Merck and Siemens have signed a memorandum of understanding (MoU) to enhance their strategic partnership, aimed at accelerating digital transformation in the life sciences sector. 

Under the expanded collaboration, the two companies aim to integrate software solutions, systems and consumables. 

They will leverage automation, data and AI to streamline drug discovery, development and manufacturing processes. 

The MoU represents the first collaborative effort using technology from Siemens' Dotmatics acquisition, completed in July 2025. 

Merck and Siemens will both focus on digital-first solutions to bridge workflow gaps in drug discovery and biomanufacturing. 

Siemens managing board member and Siemens Digital Industries CEO Cedrik Neike stated: “We are partnering with Merck to give scientists around the world the instruments to speed up the development of life-saving medication. 

“Every few years, the cost for developing a new drug is doubling. Data, AI and digitalisation are key to breaking this paradigm. 

“We are connecting every step of drug development through a digital backbone – so that data flows seamlessly, insights emerge faster and medication reaches patients faster.” 

Merck will integrate its software-as-a-service products with Siemens' digital ecosystem. 

Initial projects will include the deployment of Merck’s AI tools and digital applications within Siemens' Dotmatics Scientific Intelligence Platform, known as Luma. 

The integration will provide scientists with a unified environment linking product ordering to the digital tools necessary for making swift, data-driven decisions. 

Merck and Siemens also plan to expand their partnership by pursuing new joint projects and exploring deeper integration in the future. 

They intend to develop advanced data management tools and user-friendly interfaces to simplify complex scientific processes. 

The partnership is also considering the creation of digital marketplaces to offer streamlined access to complementary technologies and services. 

It seeks to establish a new benchmark for digital transformation, equipping scientists and manufacturers with the necessary tools to expedite breakthroughs. 

In early 2025, Merck concluded the acquisition of SpringWorks Therapeutics for up to €3bn ($3.4bn).